Display options
Cite
Adekiya TA, Aruleba RT, Khanyile S, et al. Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development. Vaccines (Basel). 2017;6(1)doi: 10.3390/vaccines6010001.
Adekiya, T. A., Aruleba, R. T., Khanyile, S., Masamba, P., Oyinloye, B. E., & Kappo, A. P. (2017). Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development. Vaccines, 6(1), . https://doi.org/10.3390/vaccines6010001
Adekiya, Tayo Alex, et al. "Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development." Vaccines vol. 6,1 (2017). doi: https://doi.org/10.3390/vaccines6010001
Adekiya TA, Aruleba RT, Khanyile S, Masamba P, Oyinloye BE, Kappo AP. Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development. Vaccines (Basel). 2017 Dec 25;6(1). doi: 10.3390/vaccines6010001. PMID: 29295563; PMCID: PMC5874642.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2017 Dec 25;6(1). doi: 10.3390/vaccines6010001.

Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development.

Vaccines

Tayo Alex Adekiya, Raphael Taiwo Aruleba, Sbonelo Khanyile, Priscilla Masamba, Babatunji Emmanuel Oyinloye, Abidemi Paul Kappo

Affiliations

  1. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].
  2. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].
  3. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].
  4. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].
  5. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].
  6. Department of Biochemistry, College of Sciences, Afe Babalola University, PMB 5454, Ado-Ekiti 360001, Nigeria. [email protected].
  7. Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa. [email protected].

PMID: 29295563 PMCID: PMC5874642 DOI: 10.3390/vaccines6010001

Abstract

Major histocompatibility complex class 1 chain-related gene sequence A is a polymorphic gene found at about 46.6 kb centromeric to HLA-B. It encodes a transmembrane protein, which is a non-classical human leukocyte antigen whose expression is normally induced by stress conditions like cancer and viral infections. The expression of MIC-A leads to the activation of NKG2D receptors of natural killer and T cells, leading to the generation of innate immune response that can easily eliminate/cleanse tumour cells and other cells that express the protein. Several bioinformatics and immunoinformatics tools were used to analyse the sequence and structure of the MIC-A protein. These tools were used in building and evaluating modelled structure of MIC-A, and to predict several antigenic determinant sites on the protein. The MIC-A protein structure generated an average antigenic propensity of 1.0289. Additionally, the hydrophilic regions on the surface of the MIC-A protein where antibodies can be attached were revealed. A total of fourteen antigenic epitopes were predicted, with six found in the transmembrane protein topology, and are predicted to play a role in the development of vaccines that can reactivate the functionalities of the MIC-A protein on the surface of cancer cells in order to elicit a desired immune response.

Keywords: 3-D structure; MIC-A; antigenic peptides; bioinformatics; cancer; epitopes; vaccine

Conflict of interest statement

The authors declare no conflict of interests.

References

  1. J Mol Biol. 2001 Jan 19;305(3):567-80 - PubMed
  2. Proc Int Conf Intell Syst Mol Biol. 1998;6:175-82 - PubMed
  3. J Biol Chem. 1982 May 10;257(9):4888-93 - PubMed
  4. J Mol Biol. 1999 Sep 17;292(2):195-202 - PubMed
  5. Nucleic Acids Res. 2010 Jan;38(Database issue):D492-6 - PubMed
  6. J Mol Biol. 1982 May 5;157(1):105-32 - PubMed
  7. J Med Chem. 2011 May 26;54(10):3606-23 - PubMed
  8. Methods Mol Biol. 1999;112:531-52 - PubMed
  9. Proteins. 2003 Feb 15;50(3):437-50 - PubMed
  10. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  11. Immunology. 2009 Sep;128(1):1-6 - PubMed
  12. Hum Immunol. 1996 Oct;50(2):127-34 - PubMed
  13. Int J Cancer. 2010 Sep 1;127(6):1412-20 - PubMed
  14. Trends Immunol. 2003 Nov;24(11):603-9 - PubMed
  15. Nucleic Acids Res. 2014 Jul;42(Web Server issue):W252-8 - PubMed
  16. Cancer Immunol Immunother. 2009 May;58(5):641-52 - PubMed
  17. Eur J Immunol. 2003 Feb;33(2):381-91 - PubMed
  18. Proteins. 1992 Apr;12(4):345-64 - PubMed
  19. Biochem Biophys Res Commun. 2006 Jul 21;346(1):175-81 - PubMed
  20. Biomed J. 2016 Dec;39(6):382-390 - PubMed
  21. Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319 - PubMed
  22. BMC Microbiol. 2010 Apr 29;10:132 - PubMed
  23. Proteins. 2009;77 Suppl 9:114-22 - PubMed
  24. FEBS Lett. 1990 Dec 10;276(1-2):172-4 - PubMed
  25. PLoS One. 2016 Oct 10;11(10 ):e0163943 - PubMed
  26. BMC Cancer. 2012 Jan 18;12:24 - PubMed
  27. Nucleic Acids Res. 2013 Jul;41(Web Server issue):W349-57 - PubMed
  28. Infect Immun. 2009 Sep;77(9):3731-9 - PubMed
  29. Immunity. 2001 Feb;14(2):123-33 - PubMed
  30. Viral Immunol. 2016 Sep;29(7):436-43 - PubMed
  31. Science. 1999 Jul 30;285(5428):727-9 - PubMed
  32. Annu Rev Immunol. 2004;22:329-60 - PubMed
  33. Oncogene. 2008 Oct 6;27(45):5932-43 - PubMed
  34. Nat Med. 2010 Mar;16(3):319-23 - PubMed
  35. Semin Cancer Biol. 2006 Oct;16(5):348-58 - PubMed
  36. Nucleic Acids Res. 2012 Jul;40(Web Server issue):W597-603 - PubMed
  37. Ann Oncol. 2007 Jul;18(7):1133-44 - PubMed
  38. Nucleic Acids Res. 2009 Jul;37(Web Server issue):W510-4 - PubMed

Publication Types